Markus R Meyer - JoVE Visualize

Showing results (131-140 of 261) with videos related to

Pageof 27

Sort By:

Toxicology Letters|March 18, 2017

In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risksLea Wagmann, Simon D Brandt, Pierce V Kavanagh, et al.

Analytical and Bioanalytical Chemistry|June 19, 2013

Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSnMarkus R Meyer, Martina Bach, Jessica Welter, et al.

Chemical Research in Toxicology|September 10, 2008

Identification of cytochrome P450 enzymes involved in the metabolism of the designer drugs N-(1-phenylcyclohexyl)-3-ethoxypropanamine and N-(1-phenylcyclohexyl)-3-methoxypropanamineChristoph Sauer, Frank T Peters, Andrea E Schwaninger, et al.

Analytica Chimica Acta|August 25, 2024

Studying drug excretion into exhaled breath aerosol - A workflow based on an impaction sampling device and LC-HRMS/MS analysisJuel Maalouli Schaar, Michael Kunz, Lea Wagmann, et al.

Toxicology Letters|August 16, 2015

Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs-Contribution of human cytochrome P450 isozymes to their main phase I metabolic stepsCarina S D Wink, Golo M J Meyer, Markus R Meyer, et al.

Talanta|July 22, 2018

Nano liquid chromatography-high-resolution mass spectrometry for the identification of metabolites of the two new psychoactive substances N-(ortho-methoxybenzyl)-3,4-dimethoxyamphetamine and N-(ortho-methoxybenzyl)-4-methylmethamphetamineAchim T Caspar, Markus R Meyer, Folker Westphal, et al.

Analytical and Bioanalytical Chemistry|November 17, 2010

Development of the first metabolite-based LC-MS(n) urine drug screening procedure-exemplified for antidepressantsDirk K Wissenbach, Markus R Meyer, Daniela Remane, et al.

Metabolites|August 26, 2021

In Vitro Metabolic Fate of the Synthetic Cannabinoid Receptor Agonists QMPSB and QMPCB (SGT-11) Including Isozyme Mapping and Esterase ActivityMatthias J Richter, Lea Wagmann, Tanja M Gampfer, et al.

Talanta|March 24, 2020

Development and application of a strategy for analyzing eight biomarkers in human urine to verify toxic mushroom or ricinus communis ingestions by means of hydrophilic interaction LC coupled to HRMS/MSThomas P Bambauer, Lea Wagmann, Hans H Maurer, et al.

Analytical and Bioanalytical Chemistry|August 15, 2014

Biotransformation and detectability of the designer drug 2,5-dimethoxy-4-propylphenethylamine (2C-P) studied in urine by GC-MS, LC-MS(n), and LC-high-resolution-MS(n)Carina S D Wink, Markus R Meyer, Tina Braun, et al.

Pageof 27

Showing results (131-140 of 261) with videos related to

Sort By:

Pageof 27

Toxicology Letters|March 18, 2017

In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risksLea Wagmann, Simon D Brandt, Pierce V Kavanagh, et al.

Analytical and Bioanalytical Chemistry|June 19, 2013

Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSnMarkus R Meyer, Martina Bach, Jessica Welter, et al.

Chemical Research in Toxicology|September 10, 2008

Identification of cytochrome P450 enzymes involved in the metabolism of the designer drugs N-(1-phenylcyclohexyl)-3-ethoxypropanamine and N-(1-phenylcyclohexyl)-3-methoxypropanamineChristoph Sauer, Frank T Peters, Andrea E Schwaninger, et al.

Analytica Chimica Acta|August 25, 2024

Studying drug excretion into exhaled breath aerosol - A workflow based on an impaction sampling device and LC-HRMS/MS analysisJuel Maalouli Schaar, Michael Kunz, Lea Wagmann, et al.

Toxicology Letters|August 16, 2015

Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs-Contribution of human cytochrome P450 isozymes to their main phase I metabolic stepsCarina S D Wink, Golo M J Meyer, Markus R Meyer, et al.

Talanta|July 22, 2018

Nano liquid chromatography-high-resolution mass spectrometry for the identification of metabolites of the two new psychoactive substances N-(ortho-methoxybenzyl)-3,4-dimethoxyamphetamine and N-(ortho-methoxybenzyl)-4-methylmethamphetamineAchim T Caspar, Markus R Meyer, Folker Westphal, et al.

Analytical and Bioanalytical Chemistry|November 17, 2010

Development of the first metabolite-based LC-MS(n) urine drug screening procedure-exemplified for antidepressantsDirk K Wissenbach, Markus R Meyer, Daniela Remane, et al.

Metabolites|August 26, 2021

In Vitro Metabolic Fate of the Synthetic Cannabinoid Receptor Agonists QMPSB and QMPCB (SGT-11) Including Isozyme Mapping and Esterase ActivityMatthias J Richter, Lea Wagmann, Tanja M Gampfer, et al.

Talanta|March 24, 2020

Development and application of a strategy for analyzing eight biomarkers in human urine to verify toxic mushroom or ricinus communis ingestions by means of hydrophilic interaction LC coupled to HRMS/MSThomas P Bambauer, Lea Wagmann, Hans H Maurer, et al.

Analytical and Bioanalytical Chemistry|August 15, 2014

Biotransformation and detectability of the designer drug 2,5-dimethoxy-4-propylphenethylamine (2C-P) studied in urine by GC-MS, LC-MS(n), and LC-high-resolution-MS(n)Carina S D Wink, Markus R Meyer, Tina Braun, et al.

Pageof 27